- Home
- NLSP vs RDHL Comparison
NLSP vs RDHL Comparison
Compare NLSP & RDHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NLSP
- RDHL
- Stock Information
- Founded
- NLSP 2015
- RDHL 2009
- Country
- NLSP Switzerland
- RDHL Israel
- Employees
- NLSP N/A
- RDHL N/A
- Industry
- NLSP Biotechnology: Pharmaceutical Preparations
- RDHL Biotechnology: Pharmaceutical Preparations
- Sector
- NLSP Health Care
- RDHL Health Care
- Exchange
- NLSP Nasdaq
- RDHL Nasdaq
- Market Cap
- NLSP 6.2M
- RDHL 6.8M
- IPO Year
- NLSP 2021
- RDHL N/A
- Fundamental
- Price
- NLSP $1.95
- RDHL $4.76
- Analyst Decision
- NLSP
- RDHL
- Analyst Count
- NLSP 0
- RDHL 0
- Target Price
- NLSP N/A
- RDHL N/A
- AVG Volume (30 Days)
- NLSP 6.1M
- RDHL 9.0K
- Earning Date
- NLSP 10-18-2024
- RDHL 04-07-2025
- Dividend Yield
- NLSP N/A
- RDHL N/A
- EPS Growth
- NLSP N/A
- RDHL N/A
- EPS
- NLSP N/A
- RDHL N/A
- Revenue
- NLSP N/A
- RDHL $3,707,000.00
- Revenue This Year
- NLSP N/A
- RDHL $224.90
- Revenue Next Year
- NLSP N/A
- RDHL $82.69
- P/E Ratio
- NLSP N/A
- RDHL N/A
- Revenue Growth
- NLSP N/A
- RDHL N/A
- 52 Week Low
- NLSP $1.71
- RDHL $4.76
- 52 Week High
- NLSP $18.40
- RDHL $20.28
- Technical
- Relative Strength Index (RSI)
- NLSP 44.06
- RDHL 26.11
- Support Level
- NLSP $2.14
- RDHL $5.20
- Resistance Level
- NLSP $2.34
- RDHL $5.50
- Average True Range (ATR)
- NLSP 0.24
- RDHL 0.23
- MACD
- NLSP -0.00
- RDHL -0.07
- Stochastic Oscillator
- NLSP 12.07
- RDHL 0.00
About NLSP NLS Pharmaceutics Ltd.
NLS Pharmaceutics Ltd is a biopharmaceutical company. It is engaged in the discovery and development of life-improving drug therapies to treat rare and complex CNS disorders. It focuses on developing therapeutics for the treatment of neurobehavioral and neurocognitive disorders. The company's tangible assets are held in the United States. Its lead products are Quilience, to treat narcolepsy and Nolazol, to treat ADHD.
About RDHL Redhill Biopharma Ltd.
Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is focused primarily on the advancement of its development pipeline of clinical-stage therapeutic candidates. The company also commercializes in the U.S. GI-related products, Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). The company's current pipeline consists of five therapeutic candidates, which are Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, most of which are in clinical development.